U.S. Life Sciences Property Report

The life sciences real estate landscape is undergoing significant transformation as we move through 2025. Following promising growth in 2024, the market now faces challenging headwinds with business, political, regulatory and funding uncertainty contributing to a decline in demand. What does this mean for investors, owners and life sciences companies navigating these complex market conditions?

The U.S. Life Sciences Property Report reveals six trends highlighting current lab market dynamics. Market equilibrium faces significant challenges that will require substantial absorption while leasing patterns undergo dramatic shift and market consolidation. Despite these challenges, there are opportunities for well-positioned landlords and investors to capitalize on the inevitable market correction and position themselves for the next wave of innovation.

Post-pandemic federal policy shifts have begun to reshore biomanufacturing

Pharmaceutical reshoring offers a bright spot amid market challenges, with $250+ billion in U.S. biomanufacturing investments announced and touring activity for manufacturing space surge.

After growing throughout 2024, lab leasing declines significantly in Q1 2025

Discover how these six trends are reshaping the lab landscape and gain valuable insights to navigate today's complex market conditions while preparing for tomorrow's opportunities.